I first came across David Nutt in July 2007, when he spoke at a conference called ‘Criminal Justice and Social Justice’, which the Centre for Crime and Justice Studies held at King’s College London. David spoke on the subject of ‘Why adopt a harm approach in relation to drugs?’. Here was someone, I thought at  …

At the end of last week, NICE released their initial appraisal on cannabidiol in the form of Epidiolex for childhood epilepsy.  As predicted by Drug Science experts they found against it on the grounds of cost-benefit. We don’t have the company submission regarding cost/benefit analysis, and consequently cannot comment on those, but we can reflect  …

Today (13th August 2019), the independent scientific body Drug Science has responded with disappointment to a decision by the National Institute for Health and Care Excellence (NICE), relating to cannabis-related medical products. In November 2018, the then Home Secretary Sajid Javid introduced regulations so that cannabis-derived medicinal products would be available on prescription. This change  …

Drug Science Patron Lord Nic Rea, hosted Drug Science committee members, trustees, and community supporters at House of Lords on Wednesday, celebrating ten years of achievements, and new initiatives in medical cannabis and psychedelic research. In the beautiful Cholmondeley Room of Westminster Palace, 150 of Drug Science’s supporters heard CEO David Badcock welcome guests and  …

Prof. Adam Winstock – Global Drug Survey 2019 As the tide of cannabis regulatory reform wafts through North America and beyond, it strikes me that the cannabis legalisation lobby started from a strong position. The weight of evidence and cogent arguments at their disposal to counter the totally unhelpful criminalisation of cannabis users was enormous.  …